- Current report filing (8-K)
17 3월 2009 - 9:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
March 17,
2009
ALLOS
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrants
telephone number, including area code:
(303)
426-6262
|
|
Not applicable
|
(Former
name or former address, if changed since last report.)
|
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Section 7 Regulation FD
Item 7.01 Regulation FD Disclosure.
On March 17, 2009,
Allos Therapeutics, Inc., a Delaware corporation (the Company), issued a
press release announcing that the European Medicines Agency, with a positive
opinion of the Committee for Orphan Medicinal Products, has granted orphan
medicinal product designation to the Companys novel antifolate, pralatrexate,
for the treatment of non-papillary transitional cell carcinoma of the urinary
bladder.
The press release is
attached hereto as Exhibit 99.1 and incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K,
the information presented under this Item 7.01 and attached as Exhibit 99.1
shall not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, except as
expressly set forth by specific reference in such a filing.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
99.1
|
|
Press
Release, dated March 17, 2009, entitled Allos Therapeutics
Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment
of Bladder Cancer by The European Commission.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: March 17, 2009
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
David C. Clark
|
|
|
David
C. Clark
|
|
Its:
|
Vice
President, Finance and Treasurer
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated March 17, 2009, entitled Allos Therapeutics
Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment
of Bladder Cancer by The European Commission.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024